MyFibroScan

FibroScan® is the first non-invasive medical device that streamlines your management of chronic liver disease, from screening to follow-up and prognosis.

Reference solution providing patented dual function capability VCTE™ (fibrosis) and CAP™ (steatosis), the FibroScan® benefits from a worldwide clinical legitimacy and is recommended in the guidelines of leading organizations.

myFibroScan app is the best companion to enlarge the suite of diagnosis tools based on FibroScan® results:

- interpret FibroScan® examination results to assess fibrosis stage and steatosis grade, according to scientific publications, etiology and examination results VCTE™ and CAP™ with the Interpretation Guide tool

- assess the probability of active NASH with the new FAST™ score, combining FibroScan® biomarkers of liver fibrosis (VCTE™) and steatosis (CAP™) with blood biomarker of liver inflammation (AST). Best-in-class diagnostic performance and broad applicability demonstrated on 1,300 patients from different clinical setting and geographical origin: consistent 0.85-0.90 average AUROCs performance